在STAMPEDE 试验中随机分配接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量...
recently published data from the Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: a multi-stage multi-arm randomised control trial (STAMPEDE). This is an innovative multi-arm multi-stage (MAMS) trial that has utilized one control arm and several comparator ...
Rush HL, MurphyL, Morgans AK, et al. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2021 Nov 10;JCO2100728. doi: 10.1200/JCO.21.00728.
在STAMPEDE 试验中随机分配接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。...
[4]mes ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 19;387:1163-77 ...
[1]annoh L. Rush, et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. 2020 ASCO-GU. Oral presentation #GU20 [2]Sydes M, et al. Adding abiraterone or doce...
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志( JCO )》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。由于多西他赛或醋酸阿比特龙联合泼尼松或泼尼松龙(AAP)在局部晚期或转移性...
which was really exciting but a little mind-blowing. What we heard discussed, though, was that STAMPEDE was predominantly de novo metastatic disease, so most of these patients came into the trial not having had treatment for their primary prostate cancer. In that population, there seemed to be...
There is more evidence at this time in the M1 setting so the confidence intervals are narrower than for M0 but one should take the overall effect from the trial; the point estimate in the M0 setting (HR = 0.75) is exactly that targeted by the protocol. However, many in the ...
该试验是根据良好临床实践指南和赫尔辛基宣言进行的,并获得了相关的伦理(西米德兰兹-埃德巴斯顿研究伦理委员会)和监管部门的批准。所有患者均给予书面知情同意。基本原理和设计,包括样本量计算,在前面已经描述过[2,3]。完整的细节在协议中 www.stampedetrial.org。